Liquid biopsy may help identify which patients with non-small cell lung cancer will benefit most from radiation

A novel liquid biopsy test may help determine which patients with non-small cell lung cancer that has spread beyond the lungs are most likely to benefit from targeted, high-dose radiation, rather than drug-based therapy, a new study suggests. Findings were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting and published in npj Precision Oncology.